Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Apriso 375 mg ER Capsules
NCT03327558Phase 1Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- May 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Salcrozine in ulcerative colitis (UC) (2 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Maximum observed plasma concentration at 3 hours. Started May 2017; status: completed.
02
Drugs
Salcrozine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03327558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03327558.